- Home
- ACRS vs NCTY Comparison
ACRS vs NCTY Comparison
Compare ACRS & NCTY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACRS
- NCTY
- Stock Information
- Founded
- ACRS 2012
- NCTY 1999
- Country
- ACRS United States
- NCTY China
- Employees
- ACRS N/A
- NCTY N/A
- Industry
- ACRS Biotechnology: Pharmaceutical Preparations
- NCTY Business Services
- Sector
- ACRS Health Care
- NCTY Consumer Discretionary
- Exchange
- ACRS Nasdaq
- NCTY Nasdaq
- Market Cap
- ACRS 132.0M
- NCTY 148.0M
- IPO Year
- ACRS 2015
- NCTY 2004
- Fundamental
- Price
- ACRS $2.24
- NCTY $16.47
- Analyst Decision
- ACRS Strong Buy
- NCTY
- Analyst Count
- ACRS 5
- NCTY 0
- Target Price
- ACRS $11.00
- NCTY N/A
- AVG Volume (30 Days)
- ACRS 656.6K
- NCTY 72.1K
- Earning Date
- ACRS 03-04-2025
- NCTY 01-01-0001
- Dividend Yield
- ACRS N/A
- NCTY N/A
- EPS Growth
- ACRS N/A
- NCTY N/A
- EPS
- ACRS N/A
- NCTY 9.91
- Revenue
- ACRS $27,079,000.00
- NCTY $24,286,983.00
- Revenue This Year
- ACRS N/A
- NCTY N/A
- Revenue Next Year
- ACRS N/A
- NCTY N/A
- P/E Ratio
- ACRS N/A
- NCTY $3.66
- Revenue Growth
- ACRS 26.35
- NCTY 2.82
- 52 Week Low
- ACRS $0.95
- NCTY $4.60
- 52 Week High
- ACRS $5.17
- NCTY $20.59
- Technical
- Relative Strength Index (RSI)
- ACRS 39.59
- NCTY 56.96
- Support Level
- ACRS $2.11
- NCTY $14.20
- Resistance Level
- ACRS $2.42
- NCTY $15.99
- Average True Range (ATR)
- ACRS 0.15
- NCTY 0.92
- MACD
- ACRS 0.00
- NCTY -0.01
- Stochastic Oscillator
- ACRS 26.53
- NCTY 85.66
About ACRS Aclaris Therapeutics Inc.
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China and other areas.